Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ana Bosch-Campos"'
Autor:
Mattias Aine, Ceren Boyaci, Johan Hartman, Jari Häkkinen, Shamik Mitra, Ana Bosch Campos, Emma Nimeus, Anna Ehinger, Johan Vallon-Christersson, Åke Borg, Johan Staaf
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-19 (2021)
Abstract Background Breast cancer in young adults has been implicated with a worse outcome. Analyses of genomic traits associated with age have been heterogenous, likely because of an incomplete accounting for underlying molecular subtypes. We aimed
Externí odkaz:
https://doaj.org/article/4912f58ed9244a1e8245e5010d96291a
Autor:
Mattias Aine, Ceren Boyaci, Johan Hartman, Jari Häkkinen, Shamik Mitra, Ana Bosch Campos, Emma Nimeus, Anna Ehinger, Johan Vallon-Christersson, Åke Borg, Johan Staaf
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-2 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/3660aa64683849c0a47efc9eaf8c9b40
Autor:
Gudbjörg Sigurjonsdottir, Tommaso De Marchi, Anna Ehinger, Johan Hartman, Ana Bosch Campos, Johan Staaf, Fredrika Killander, Emma Niméus
Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC). However, IHC evaluation methods are non-uniform and further studies are needed to op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e93acd815bbd902f945aa7b2b6aa3df3
https://doi.org/10.21203/rs.3.rs-2841893/v1
https://doi.org/10.21203/rs.3.rs-2841893/v1
Autor:
Sophie Lehn, Gyula Pekar, Paulina Bolivar Balbas, Johan Staaf, Christina Möller, Kristina Lövgren, Anna Ehinger, Ana Bosch Campos, Åke Borg, Kristian Pietras
Publikováno v:
Cancer Research. 83:P6-01
Around 10-15% of all breast cancers are categorized clinically as triple-negative breast cancer (TNBC). TNBC is defined by lack of protein expression or over expression of treatment targets such as the Estrogen Receptor α (ER) and Human Epidermal Gr
Autor:
Ana Bosch Campos, Shamik Mitra, Ceren Boyaci, Johan Vallon-Christersson, Mattias Aine, Anna Ehinger, Johan Hartman, Åke Borg, Emma Niméus, Johan Staaf, Jari Häkkinen
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 23, Iss 1, Pp 1-19 (2021)
Breast Cancer Research, Vol 23, Iss 1, Pp 1-19 (2021)
Background Breast cancer in young adults has been implicated with a worse outcome. Analyses of genomic traits associated with age have been heterogenous, likely because of an incomplete accounting for underlying molecular subtypes. We aimed to resolv
Autor:
Anna Ehinger, Mattias Aine, Ceren Boyaci, Jari Häkkinen, Shamik Mitra, Johan Hartman, Johan Vallon-Christersson, Johan Staaf, Emma Niméus, Åke Borg, Ana Bosch Campos
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-2 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Autor:
P. Kim, Jeffrey A. Engelman, Maurizio Scaltriti, Vanessa Rodrik-Outmezguine, Saswati Hazra, Yasir H. Ibrahim, J. Baselga, Violeta Serra, Natasha Morse, Dejan Juric, Taru A. Muranen, Ana Bosch Campos, Jessica J. Tao, Manway Liu, Alan Huang, Mari Mino-Kenudson, Jordi Rodon Ahnert, Cornelia Quadt, Sadhna Vora, Moshe Elkabets, Sharat Singh, Neal Rosen
Publikováno v:
Science Translational Medicine. 10
Autor:
Sarat Chandarlapaty, Vanessa Rodrik-Outmezguine, Maurizio Scaltriti, Zhiqiang Li, Baselga José, Michael F. Berger, Neal Rosen, Sarit Schwartz, Ana Bosch-Campos, Marie Will
Publikováno v:
Cancer Research. 75:P1-17
Background: Activation of PI3K alpha is among the most frequent oncogenic events in breast transformation, commonly occurring through mutations in the p110 alpha subunit of PI3K or amplification of the HER2 receptor tyrosine kinase. Therapeutic targe
Autor:
Yasir H. Ibrahim, Sharat Singh, Ana Bosch Campos, Neal Rosen, Moshe Elkabets, Jeffrey A. Engelman, Natasha Morse, José Baselga, Alan Huang, P. Kim, Dejan Juric, Sadhna Vora, Vanessa Rodrik-Outmezguine, Jordi Rodon, Manway Liu, Maurizio Scaltriti, Taru A. Muranen, Saswati Hazra, Cornelia Quadt, Jessica J. Tao, Violeta Serra, Mari Mino-Kenudson
Activating mutations of the PIK3CA gene occur frequently in breast cancer, and inhibitors that are specific for phosphatidylinositol 3-kinase (PI3K) p110α, such as BYL719, are being investigated in clinical trials. In a search for correlates of sens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bfa575a0ac1edcb4e0fc1760bf39781
https://europepmc.org/articles/PMC3935768/
https://europepmc.org/articles/PMC3935768/
Autor:
Dejan Juric, Sadhna Vora, Liu Manway, Sharat Singh, José Baselga, Moshe Elkabets, Jordi Rodon, Taru A. Muranen, Alan Huang, Yasir H. Ibrahim, Maurizio Scaltriti, Cornelia Quadt, Neal Rosen, Natasha Morse, P. Kim, Ana Bosch Campos, Saswati Hazra, Vanessa Rodrik-Outmezguine, Jeffrey A. Engelman, Jessica J. Tao, Violeta Serra, Mari Mino-Kenudson
Publikováno v:
Molecular Cancer Therapeutics. 12:B106-B106
Activating mutations of the PIK3CA gene occur frequently in breast cancer and inhibitors that are specific for PI3K p110α, such as BYL719, are being investigated in clinical trials. In a search for correlates of sensitivity to p110α inhibition amon